PATIENT-SPECIFIC STEM CELL LINES DERIVED FROM HUMAN PARTHENOGENETIC BLASTOCYSTS Russian patent published in 2014 - IPC C12N5/71 

FIELD: chemistry.

SUBSTANCE: invention relates to biotechnology. described are methods for generating HLA homozygous parthenogenetic human stem cell (hpSC-Hhom) lines from both HLA homozygous and HLA heterozygous donors. These hpSC-Hhom lines demonstrate typical human embryonic stem cell morphology, expressing appropriate stem cell markers and possessing high levels of alkaline phosphatase and telomerase activity. Additionally, injection of these cell lines into immunodeficient animals leads to teratoma formation. Furthermore, in the case of HLA heterozygous donors, the hpSC-Hhom lines inherit the haplotype from only one of the donor's parents. SNP data analysis suggests that hpSC-Hhom lines derived from HLA heterozygous oocyte donors are homozygous throughout the genome as assessed by single-nucleotide polymorphism (SNP) analysis.

EFFECT: described protocol minimises the use of animal-derived components, which makes the stem cells more suitable for clinical application.

13 cl, 11 dwg, 15 tbl, 2 ex